DMT-310 is under clinical development by Dermata Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect DMT-310’s likelihood of approval (LoA) and phase transition for Acne Vulgaris took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their DMT-310 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
DMT-310 is under development for the treatment of acne vulgaris, psoriasis and it was under development for the treatment of papulopustular rosacea. The drug candidate is a variant of sponge administered topically. It is developed based on the Spongilla platform technology.
Dermata Therapeutics overview
Dermata Therapeutics is a biotechnology company. It discovers, develops and commercializes treatments for medical and aesthetic skin conditions. The company is investigating its lead product candidate DMT310, a natural source of spongilla lacustris with multiple active components to treat inflammatory skin diseases including acne, psoriasis and rosacea. It is also evaluating DMT400, a combination regimen of biologic molecules against various skin diseases and cosmetic applications; and DMT410 drug developed in combination with botulinum toxin for the treatment of hyperhidrosis and aesthetics. The company utilizes its proprietary Spongilla platform technology to develop its products. Dermata Therapeutics is headquartered in San Diego, California, the US.
Quick View DMT-310 LOA Data
|Highest Development Stage|